A 48-year-old Indian woman with Type 2 diabetes and hypertension presents with recurrent transient ischaemic attacks (TIAs). Her lipid profile shows: Total cholesterol 240 mg/dL, LDL-C 140 mg/dL, HDL-C 32 mg/dL, Triglycerides 380 mg/dL. She is on metformin and amlodipine. On further questioning, her mother has diabetes and elevated triglycerides. Genetic testing reveals a heterozygous APOE2/E3 genotype and a mutation in the APOC3 gene. Which lipoprotein fraction is most likely elevated and driving her atherogenic dyslipidaemia?

Explanation

## Atherogenic Dyslipidaemia in Type 2 Diabetes and APOC3 Mutation ### Clinical Presentation Analysis **Key Point:** This patient presents with the classic triad of atherogenic dyslipidaemia: elevated triglycerides (380 mg/dL), low HDL-C (32 mg/dL), and premature atherosclerotic vascular disease (TIAs). ### Role of APOC3 Gene Mutation APOC3 encodes apolipoprotein C-III, a key regulator of lipoprotein metabolism: 1. **Normal APOC3 function**: Inhibits lipoprotein lipase (LPL) and hepatic lipase, slowing triglyceride hydrolysis 2. **APOC3 mutation (loss-of-function)**: Typically reduces APOC3 levels, enhancing LPL activity and triglyceride clearance 3. **However**, in this patient, the clinical picture suggests **impaired remnant clearance**, which can occur with APOC3 variants that affect hepatic uptake of remnants ### Pathophysiology of Atherogenic Dyslipidaemia ```mermaid flowchart TD A[Type 2 Diabetes + Insulin Resistance]:::outcome --> B[Increased hepatic VLDL production]:::action B --> C[High triglycerides in circulation]:::outcome C --> D[Triglyceride-rich VLDL and chylomicrons]:::outcome D --> E[CETP-mediated lipid exchange]:::action E --> F[Triglyceride enrichment of LDL & HDL]:::outcome F --> G[Small dense LDL particles]:::urgent F --> H[Low HDL-C]:::urgent G --> I[Increased atherogenicity]:::urgent H --> I ``` ### Why Remnants Accumulate - **Chylomicron remnants**: Derived from dietary triglycerides; normally cleared by hepatic LDL receptors and LRP1 - **VLDL remnants (IDL)**: Produced by lipoprotein lipase action on VLDL; converted to LDL or cleared directly - **Small dense LDL**: Formed when LDL particles are enriched with triglycerides (via CETP) and depleted of cholesteryl esters - **Impaired clearance**: APOC3 variants and insulin resistance reduce hepatic uptake of remnants, causing accumulation ### Comparison of Dyslipidaemia Types | Feature | Atherogenic Dyslipidaemia | Familial APOC3 Deficiency | Type IIb Hyperlipoproteinaemia | |---------|---------------------------|--------------------------|-------------------------------| | Triglycerides | ↑↑ (200–500) | ↓ (very low) | ↑↑ (200–500) | | LDL-C | Normal to ↑ | ↓ | ↑↑ | | HDL-C | ↓↓ | ↑ | ↓ | | LDL particle size | Small dense | Large buoyant | Mixed | | Atherosclerosis risk | Very high | Very low | High | | Associated with | T2DM, obesity, IR | Genetic protection | Familial clustering | **High-Yield:** Small dense LDL particles are more atherogenic than large buoyant LDL because they: - Penetrate arterial intima more readily - Are more susceptible to oxidation - Bind less avidly to LDL receptors (prolonged circulation) - Promote greater foam cell formation **Mnemonic:** **VLDL-R** = VLDL Remnants, Lipoprotein Lipase, Remnant clearance defect → atherogenic dyslipidaemia **Clinical Pearl:** In Type 2 diabetes, insulin resistance drives hepatic VLDL overproduction and impairs remnant clearance. APOC3 mutations can exacerbate this by altering the clearance pathway, leading to accumulation of triglyceride-rich remnants and small dense LDL particles.